Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
|Table 1. Assignment of predicted MT-RNR1 phenotype based on genotype|
|Table 2. Recommended therapeutic use of aminoglycosides in relation to MT-RNR1 phenotype in children and adults|
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021)
Tables provided in the guideline publication supplement or referenced in the guidelinea:
|Supplemental Table S1. Evidence linking MT-RNR1 genotype with Aminoglycoside-Induced Hearing Loss|
|MT-RNR1 allele definition table|
|MT-RNR1 allele functionality table|
|MT-RNR1 frequency table|
|Gene resource mapping|
|Drug resource mapping|
|Clinical decision support:b|
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.